# RIVER PDAC (NCT06989437)

> A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06989437
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions: ponsegromab; placebo
- Enrollment: 982
- Primary outcome: Percent change from baseline in body weight for ponsegromab compared to placebo
- Primary outcome: Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores

## Indexed commentary on RIVER PDAC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=river-pdac-nct06989437